Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration

Ophthalmology

Volumn 120, Issue 12, 2013, Pages 2620-2629

  Mayr Sponer, Ulrike ^a   Waldstein, Sebastian M ^a   Kundi, Michael ^a   Ritter, Markus ^a   Golbaz, Isabelle ^a   Heiling, Ursula ^a   Papp, Andrea ^a   Simader, Christian ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CENTRAL RETINAL THICKNESS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY DETACHMENT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETREATMENT; TISSUE ADHESION; VITREOUS BODY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RETINAL DISEASES; RETREATMENT; TISSUE ADHESIONS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 84888016133     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.05.032     Document Type: Article

References (32)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study Ophthalmology 116 2009 57 65
4. B.A. Keyt, L.T. Berleau, and H.V. Nguyen The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency J Biol Chem 271 1996 7788 7795
5. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504
6. J.S. Penn, A. Madan, and R.B. Caldwell Vascular endothelial growth factor in eye disease Prog Retin Eye Res 27 2008 331 371
7. S. Grisanti, and O. Tatar The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration Prog Retin Eye Res 27 2008 372 390
8. J. Lowe, J. Araujo, and J. Yang Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp Eye Res 85 2007 425 430
9. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
10. C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye (Lond) 25 2011 661 672
11. M. Funk, D. Karl, and M. Georgopoulos Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab Ophthalmology 116 2009 2393 2399
12. CATT Research Group D.F. Martin, M.G. Maguire, and G.S. Ying Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
13. IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
14. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
15. P. Mitchell, J.F. Korobelnik, and P. Lanzetta Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials Br J Ophthalmol 94 2010 2 13
16. M. El Sanharawi, L. Kowalczuk, and E. Touchard Protein delivery for retinal diseases: from basic considerations to clinical applications Prog Retin Eye Res 29 2010 443 465
17. R.Y. Foos Vitreoretinal juncture; topographical variations Invest Ophthalmol 11 1972 801 808
18. J. Sebag, and E.A. Balazs Morphology and ultrastructure of human vitreous fibers Invest Ophthalmol Vis Sci 30 1989 1867 1871
19. M.M. Le Goff, and P.N. Bishop Adult vitreous structure and postnatal changes Eye (Lond) 22 2008 1214 1222
20. J. Sebag Age-related changes in human vitreous structure Graefes Arch Clin Exp Ophthalmol 225 1987 89 93
21. J. Sebag Age-related differences in the human vitreoretinal interface Arch Ophthalmol 109 1991 966 971
22. M.W. Johnson Perifoveal vitreous detachment and its macular complications Trans Am Ophthalmol Soc 103 2005 537 567
23. E. Uchino, A. Uemura, and N. Ohba Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography Arch Ophthalmol 119 2001 1475 1479
24. I. Krebs, W. Brannath, and C. Glittenberg Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 144 2007 741 746
25. Y. Nomura, T. Ueta, and A. Iriyama Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy Ophthalmology 118 2011 853 859
26. F. Mojana, L. Cheng, and D.U. Bartsch The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results Am J Ophthalmol 146 2008 218 227
27. C.D. Robison, I. Krebs, and S. Binder Vitreomacular adhesion in active and end-stage age-related macular degeneration Am J Ophthalmol 148 2009 79 82
28. S.J. Lee, C.S. Lee, and H.J. Koh Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study Am J Ophthalmol 147 2009 621 626
29. S.M. Waldstein, U. Sponer, and C. Simader Influence of vitreomacular adhesion on the development of exudative age-related macular degeneration: 4-year results of a longitudinal study Retina 32 2012 424 433
30. S.J. Lee, and H.J. Koh Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration Ophthalmology 118 2011 101 110
31. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study Ophthalmology 118 2011 831 839
32. M.A. Singer, C.C. Awh, and S. Sadda HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 2012 1175 1183